Coreg. Buy more. Save more.

M2 PRESSWIRE-23 October 2006-www.MarketGainer.com: Notifies Shareholders of Flamel Technologies(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:23102006 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today’s activity on the Nasdaq exchange has brought Flamel Technologies (NASDAQ:FLML) to the attention of our research team.

Related Results

Trial data added to c…

Caraco Pharmaceutical Laboratories Ltd. has received tentative approval for generic Coreg tablets. The product (carvedilol) is for teating mild to severe heart failure of ischemic or cardiomyopathic origin.

Related Results

Trial data added to coreg labelNew indications for once-daily CoregFlamel T…

The Food and Drug Administration has approved a new application for Coreg CR (carvedilol phosphate) extended-release capsules for the treatment of mild to severe heart failure, the reduction of cardiovascular mortality in patients who have survived the acute phase of myocardial infarction, and hypertension.

Related Results

Trial data added to coreg labelFlamel Technologies Welcomes FDA Approval of COREG CR™Fla…

The world’s largest generics company is also expected to be strong in biogenerics. In 2004, Teva purchased Sicor, which markets G-CSF, human growth hormone and interferon alpha in Eastern Europe and emerging markets. Gate, a subsidiary of Teva, sells human growth hormone in the United States as branded Tev-Tropin.
In 2005, Teva acquired Ivax, which is developing generic insulin and human grow…

Jan. 9, 2007 — For heart attackheart attack survivors, it really is important to
follow doctor’s orders: A Canadian study shows you may be less likely to die if
you continue taking the drug he prescribes.
The study of 31,455 heart attack survivors found 24% of the patients worst
about continuing their medicine died over the course of the study, compared to
16% of those best at taking their medication.
The patients, who were …

CHICAGO — The Fitch Ratings global pharmaceutical team is presenting its ‘Global Pharmaceutical R&D Pipeline’ report for the third quarter, today. The overview details the most current developments of late-stage R&D brand name pharmaceutical projects of major drug developers and provides details about relevant industry issues.
Successful R&D is more critical for the industry compared to previous years, in orde…

Flamel’s Medusa([R]) technology designed to allow less frequent administration of therapeutic proteins and peptides
LYON, France — Flamel Technologies (Nasdaq:FLML) today announced that it has entered into a collaboration with Merck Serono, a division of Merck KGaA, to investigate the applicability of Flamel’s Medusa([R]) technology for the extended release of a therapeutic protein of Merck Serono’s portfolio. Unde…